# Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19

> **NCT05675943** · NA · COMPLETED · sponsor: **Beijing Boren Hospital** · enrollment: 31 (actual)

## Conditions studied

- Hematological Disorders
- COVID-19

## Interventions

- **BIOLOGICAL:** Anti-COVID-19 Antibody SA55 for Injection

## Key facts

- **NCT ID:** NCT05675943
- **Lead sponsor:** Beijing Boren Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-12
- **Primary completion:** 2024-04-03
- **Final completion:** 2024-04-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05675943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05675943, "Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05675943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*